Asia More “Enlightened” Regulatory Environment – Pharmaxis CEO
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis will submit its marketing authorization application for chronic lung condition drug Bronchitol to Australia's Therapeutic Good Administration in the third quarter of 2008